--- title: "Pacira BioSciences (PCRX) news: merger and buyback" url: "https://aibio.space/companies/pacira-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PCRX merger and buyback news: Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash. Pacira BioSciences, Inc." --- PCRX Pacira BioSciences, Inc. NASDAQ · United States # Pacira BioSciences (PCRX) news PCRX merger and buyback news Mergers · 2026-10-08 ## [Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash](https://aibio.space/news/viatris-agrees-acquire-pacira-biosciences-36-50-share-cash/) Viatris agreed to buy Pacira for $36.50 a share in cash, an equity value of $1.65 billion, through a tender offer and a second-step merger. The release states no premium to the recent share price. ## Latest Pacira BioSciences news 1. 2025-07-10 Distress [Pacira BioSciences announces workforce reduction of 71 employees, about 8% of staff](https://aibio.space/news/pacira-biosciences-announces-workforce-reduction-71-employees-about-8/) Pacira is shutting down its 45-liter EXPAREL suite in San Diego and cutting 71 employees, about 8% of its workforce. It expects $2.4 million to $2.8 million of cash charges in the third quarter and about $13 million a year in lower operating expenses. 2. 2025-07-10 Distress [Pacira BioSciences cuts about 70 jobs as it decommissions 45-liter EXPAREL facility](https://aibio.space/news/pacira-biosciences-cuts-about-70-jobs-decommissions-45-liter-exparel/) Pacira is closing its 45-liter EXPAREL manufacturing system and cutting about 70 Technical Operations jobs, and the employee note it filed says the larger 200-liter process in San Diego and Swindon now supplies the product. 3. 2025-07-07 Debt Financing [Pacira BioSciences enters $300.0 million revolving credit facility, repays term loan A](https://aibio.space/news/pacira-biosciences-enters-300-0-million-revolving-credit-facility/) The July 3, 2025 credit agreement is a $300.0 million senior secured revolver maturing July 3, 2030, and Pacira used part of it to repay its term loan A without prepayment penalties or fees. Wells Fargo Bank is administrative agent, and Wells Fargo Securities, Citizens Bank and Truist Securities are joint bookrunners and lead arrangers. 4. 2025-07-07 Distress [Pacira signs $300.0 million revolving credit facility and repays term loan](https://aibio.space/news/pacira-signs-300-0-million-revolving-credit-facility-repays-term-loan/) Pacira signed a $300.0 million senior secured revolving credit facility with Wells Fargo as administrative agent, and used part of it to repay its 2023 term loan A. The filing does not say how much was drawn. 5. 2025-04-22 Financings [Pacira BioSciences approves new buyback of up to $300.0 million](https://aibio.space/news/pacira-biosciences-approves-new-buyback-up-300-0-million/) Pacira BioSciences says its board approved a $300.0 million repurchase program on April 17, 2025, replacing the program announced in May 2024, while EXPAREL still accounts for most of its revenue. ## Pacira BioSciences at a glance - **Ticker**: PCRX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $251.0 million ### Related companies - [Mustang Bio](https://aibio.space/companies/mustang-bio/) NASDAQ: MBIO - [Viatris](https://aibio.space/companies/viatris/) NASDAQ: VTRS - [Alnylam Pharmaceuticals](https://aibio.space/companies/alnylam-pharmaceuticals/) NASDAQ: ALNY - [Cumberland Pharmaceuticals](https://aibio.space/companies/cumberland-pharmaceuticals/) NASDAQ: CPIX - [Lifecore Biomedical](https://aibio.space/companies/lifecore-biomedical/) NASDAQ: LFCR - [ARS Pharmaceuticals](https://aibio.space/companies/ars-pharmaceuticals/) NASDAQ: SPRY - [MannKind](https://aibio.space/companies/mannkind/) NASDAQ: MNKD - [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) NASDAQ: MIRM ### Also on NASDAQ - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) DMAC - [Virax Biolabs Group](https://aibio.space/companies/virax-biolabs/) VRAX - [Greenwich LifeSciences](https://aibio.space/companies/greenwich-lifesciences/) GLSI - [QT IMAGING HOLDINGS, INC.](https://aibio.space/companies/qt-imaging/) QTI - [Aligos Therapeutics](https://aibio.space/companies/aligos-therapeutics/) ALGS - [Aktis Oncology](https://aibio.space/companies/aktis-oncology/) AKTS ## What Pacira BioSciences does Pacira BioSciences is focused on non-opioid pain therapies. It has three commercialized non-opioid treatments: EXPAREL, its flagship long-acting local analgesic approved for postsurgical pain management; ZILRETTA, an extended-release intra-articular corticosteroid injection indicated for osteoarthritis knee pain; and iovera, a handheld device that delivers precisely controlled doses of cold temperature to a targeted nerve for drug-free pain control. Its pipeline includes PCRX-201, enekinragene inzadenovec, a locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. PCRX-201 is the lead program from Pacira's proprietary high-capacity adenovirus, or HCAd, vector platform, which the company says enables local administration of genetic medicines for large prevalent diseases. The company says its mission is to deliver innovative, non-opioid pain therapies to transform the lives of patients. | Product or program | What it is | Stage | |---|---|---| | EXPAREL | Long-acting local analgesic for postsurgical pain | Approved | | ZILRETTA | Extended-release intra-articular corticosteroid for osteoarthritis knee pain | Commercial | | iovera | Handheld device delivering cold temperature to a targeted nerve | Commercial | | PCRX-201 (enekinragene inzadenovec) | Locally administered gene therapy for osteoarthritis of the knee | Phase 2 | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/pcrx-20251231.htm). ## Pacira BioSciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$117.3 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/) | [$81.6 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/) | | Net income (loss) | [$7.0 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/) | [-$99.6 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/) | | Cash from operations | [$152.0 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/) | [$189.4 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/) | | Cash and equivalents | [$158.5 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/) | [$276.8 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/) | | Short-term investments | [$79.9 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/) | [$207.8 million](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $205.9 million, plus short-term investments of $45.2 million, $251.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Pacira BioSciences Is Pacira BioSciences involved in a merger or acquisition? Our latest story on this, dated Oct 8, 2026: "Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/viatris-agrees-acquire-pacira-biosciences-36-50-share-cash/). Does Pacira BioSciences have a share buyback? Our latest story on this, dated Apr 22, 2025: "Pacira BioSciences approves new buyback of up to $300.0 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pacira-biosciences-approves-new-buyback-up-300-0-million/). What is the ticker symbol of Pacira BioSciences? Pacira BioSciences, Inc. trades under the ticker PCRX on NASDAQ. Where is Pacira BioSciences listed? Pacira BioSciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:82P. What is the SEC CIK of Pacira BioSciences? The SEC Central Index Key (CIK) for Pacira BioSciences, Inc. is 1396814. Its filings are on SEC EDGAR. How many shares does Pacira BioSciences have outstanding? 39,861,886 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Pacira BioSciences listed under? Our directory records Pacira BioSciences, Inc. under United States. What does Pacira BioSciences do? Our directory classifies Pacira BioSciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Pacira BioSciences? The ISIN recorded for Pacira BioSciences, Inc. is US6951271005. Does aibio.space cover Pacira BioSciences? aibio.space lists Pacira BioSciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Pacira BioSciences incorporated? SEC records list its state or country of incorporation as DE. What does Pacira BioSciences develop? Pacira BioSciences is focused on non-opioid pain therapies. It has three commercialized non-opioid treatments: EXPAREL, its flagship long-acting local analgesic approved for postsurgical pain management; ZILRETTA, an extended-release intra-articular corticosteroid injection indicated for osteoarthritis knee pain; and iovera, a handheld device that delivers precisely controlled doses of cold temperature to a targeted nerve for drug-free pain control. What is EXPAREL from Pacira BioSciences? EXPAREL: Long-acting local analgesic for postsurgical pain Stage: Approved. What is ZILRETTA from Pacira BioSciences? ZILRETTA: Extended-release intra-articular corticosteroid for osteoarthritis knee pain Stage: Commercial. Is Pacira BioSciences profitable? Pacira BioSciences, Inc. reported net income of $7.0 million for the fiscal year ended Dec 31, 2025, and generated $152.0 million of cash from operations, per its annual report to the SEC. ## Investor discussion: Pacira BioSciences Members talk about Pacira BioSciences (PCRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Pacira BioSciences, newest first. Each line links the filing it comes from. 1. 2026-10-08 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/tm2627240d2_ex99-1.htm) 2. 2025-07-10 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000093/sccrifsummer2025-ex991.htm) 3. 2025-07-07 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1396814/000110465925065979/tm2519804d1_8k.htm) 4. 2025-04-22 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000055/pcrx-20250417.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PCRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-PCRX/). ## SEC filings and registration - **SEC name**: Pacira BioSciences, Inc. - **CIK**: 1396814 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PCRX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005 - **Phone**: 650-242-8052 - **Shares outstanding**: 39,861,886 as of 2026-08-03 (10-Q filed 2026-08-04) - **Former names**: Pacira Pharmaceuticals, Inc.; PACIRA INC; Blue Acquisition Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/tm2627240d2_8k.htm) filed 2026-10-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/pcrx-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-20260804.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1396814/000162828026046136/pcrx-20260628.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/pcrx-20260609.htm) filed 2026-06-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/pcrx-20260331.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/pcrx-20260430.htm) filed 2026-04-30 - [10-K](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/pcrx-20251231.htm) filed 2026-02-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001396814), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Pacira BioSciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PCRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Pacira BioSciences, Inc. - **Ticker**: PCRX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6951271005 - **Other listed symbols**: GETTEX:82P - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PCRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pacira-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Pacira BioSciences (PCRX) news: merger and buyback", 2026-10-31, https://aibio.space/companies/pacira-biosciences/